INTRODUCTION
Tuberculosis (TB), originating over 400 centuries ago in Africa, is caused by Mycobacterium tuberculosis. Killing currently > 3,500 people every day, TB continues to be a first-class health priority in terms of incidence and mortality, together with HIV/AIDS and malaria. The 2014 World Health Organization (WHO) Global Report estimates that nine million incident cases of TB and 1.5 million deaths occurred in 2013 1 .
The rise in the number of M. tuberculosis isolates resistant to first-line (multidrug-resistant TB [MDR-TB], i.e. resistant to at least isoniazid and rifampicin) and second-line (extensively drug resistant [XDR] , i.e. resistant to any fluoroquinolones and to at least one of the second-line injectable drugs, amikacin, capreomycin, and kanamycin on top of isoniazid and rifampicin) drugs is posing a real threat to global TB control and elimination efforts [2] [3] [4] [5] . The WHO estimated that in 2013, the prevalence of MDR-TB among the new and re-treated cases was, respectively, 3.5 and 20.5%, with 9% of them being XDR-TB 1, 6 . Unfortunately, at the global level, out of the estimated 300,000 MDR-TB cases, only 136,000 (45.3%) are diagnosed and 97,000 (32.3%) are treated using adequate regimens based on drug-susceptibility testing (DST). Consequently, the treatment success rate of MDR-TB is low (48%), and that of the XDR-TB cases with advanced resistance patterns is very low (< 20%) 1, 7, 8 .
The aim of the present review is to update the reader on the principles of modern anti-TB treatment, describe the regimens recommended by the WHO for drug-resistant and MDR/XDR-TB cases, and describe the trials presently ongoing on new regimens vis-à-vis the availability of new drugs like delamanid, bedaquiline, and pretomanid.
A non-systematic review based on historical trials results as well as on recent literature and WHO guidelines has been performed.
The rationale of modern short-course chemotherapy
Mycobacterium tuberculosis is a slow-growing aerobic organism with the capacity to remain dormant for long periods of time. Prolonged treatment with multiple drugs is then necessary to ensure both relapse-free cure and prevention of drug-resistance. The results of any treatment effort are determined by a combination of bacteriological (e.g. number and metabolic conditions of the bacilli), environmental (anatomical and biochemical; e.g. oxygen tension and pH level) and pharmacological factors (e.g. drug dosage, combination and treatment duration) [9] [10] [11] .
Preventing the emergence of drug resistance, as early studies from 1960s have demonstrated 11 , is of paramount importance; at least two active drugs are necessary as mono-therapy leads to treatment failure and relapse.
There are three main actions of anti-TB drugs [9] [10] [11] : -Bactericidal action, e.g. the ability to rapidly kill actively growing bacilli, i.e. isoniazid (H), and to a lesser extent rifampicin (R), pyrazinamide (Z) and streptomycin (S); -Sterilizing action, e.g. the capacity to kill the semi-dormant organisms, e.g. R and Z; and -Prevention of emergence of bacillary resistance, e.g. H and R; and, with a lower efficacy, S, ethambutol (E) and Z.
Anti-TB treatment has an intensive and a continuation phase. The intensive phase of treatment kills both actively growing and semi-dormant bacilli, ensuring individual benefit for the patient, and reducing transmission in the community as well as the probability to select resistant mutants. During the intensive phase of treatment, at least two bactericidal drugs (H and S or H and R) are necessary. Z is added because of its brilliant activity in the acidic environment of the pulmonary cavities, and its capacity to kill semi-dormant bacilli not destroyed by other drugs. E, although bacteriostatic, is helpful in case of initial resistance to a single drug or when the initial bacillary load is high.
Appropriate multidrug combinations (including 3-5 drugs) are likely to contain at least two drugs able to kill the pre-existing mono-drug-resistant spontaneous mutants among wild strains. In case of mono-resistance to a first-line drug (R excluded), the chances of a favorable outcome are reasonably high if four drugs are prescribed in the intensive phase of treatment 12 .
The continuation phase (usually including H and R for new cases) eliminates most residual bacilli, reducing the probability of failure and relapse. As the bacilli are no longer replicating actively, the probability of selecting drug-resistant mutants is low 13 . The current 2004 WHO-recommended treatment regimens for new cases, approved TB   drugs, and their dosage are summarized in  table 1 . The WHO has started the procedures to revise these guidelines.
MANAGING DRUG-SUSCEPTIBLE TUBERCULOSIS
The recommendations 14 clearly distinguish between new cases (e.g. patients diagnosed with TB, who have never previously received anti-TB drugs for more than one month) and retreatment cases (e.g. those treated previously for more than 30 days). New TB cases (irrespective of HIV-status) should be treated with a six-month regimen of HRZE for the first two months ("intensive phase"), followed by HR for the remaining four months ("continuation phase") 14 . Longer treatments are not recommended as clinical trials have not not confirmed clinical superiority.
Although daily dosage is recommended for the entire duration of treatment (and particularly during the intensive phase), the threetimes weekly approach is allowed if directly observed therapy is ensured.
Fixed-dose combination formulations are recommended to treat TB, based on evidence of no significant differences between fixed-dose combinations and separate TB drug formulations in acquiring drug resistance, achieving bacteriological conversion, or producing adverse events 15 . Furthermore, fixed-dose combinations simplify TB therapy at the programmatic level, although no evidence exists that these formulations improve treatment outcomes or patient adherence.
The WHO has recently published its new "End TB Strategy" 1,16 based on three pillars: the first pillar includes prevention, diagnostic and treatment interventions, the second the socio-economic interventions beyond the TB programmatic level (e.g. universal access, social protection, etc.) and the third, the research priorities.
As part of pillar 1, universal drug susceptibility testing (rapid DST with, for example GeneXpert 17 and/or conventional with solid or liquid culture) is strongly recommended before prescribing the anti-TB regimen; however, this is not universally available yet in several developing countries. Re-treatment patients need special attention because of the risk of inducing drug resistance. Rapid tests for DST should be used whenever available to ensure an appropriate treatment regimen from the beginning as well as adequate infection control management in a specialized MDR-TB Centre 18, 19 . While awaiting DST results, these patients could be initially treated with an empiric regimen (i.e. HRZES for two months, followed by HRZE for one month and HRE for five months) only in settings where the prevalence of MDR-TB is medium or low.
MANAGING MULTIDRUG RESISTANT AND EXTENSIVELY DRUG RESISTANT TUBERCULOSIS
The emergence and spread of MDR-and XDR-TB has attracted interest at different levels 1, [20] [21] [22] [23] . Recently, M. tuberculosis strains that are resistant to all known drugs have been described in Italy 24 as well as in India and Iran [25] [26] [27] , leading to the new definition of "total drug resistance". However, this definition has not been approved by the WHO due to the difficulty to standardize the panel of drugs to be tested vis-à-vis the new drugs gradually entering in the anti-TB treatment arena.
From the public health point of view, MDR/ XDR-TB is considered a serious threat for TB control and elimination 1, 21 .
The prevalence of MDR-TB is particularly high in several countries belonging to the former Soviet Union, where 9-35% of new cases and ≥ 50% of previously treated cases harbor MDR-TB strains 1 .
XDR-TB had been reported by 100 countries worldwide. Overall, 75 countries plus five territories globally reported representative data on the proportion of MDR-TB cases affected by XDR-TB, being 9% (95% CI: 6. We have mentioned above how unsatisfactory the clinical outcome of MDR-TB cases is 1, 6, 29, 30 . In the largest ever-published cohort of 9,153 MDR-TB cases from 32 observational cohorts supporting an individual data meta-analysis, the clinical outcomes were unacceptably poor (treatment success 54%; default 23%; failure/ relapse 8%; death 15%) 31 . In XDR-TB cases and cases with resistance patterns beyond XDR, the outcomes were even worse, with treatment success ranging from 19 to 40%, failure/relapse from 15 to 54%, and death from 15 to 35% 7, 8 .
The challenges clinicians face when dealing with MDR-and XDR-TB cases include frequent occurrence of adverse events, limited availability of second-line anti-TB drugs, the relevant risk of acquiring further M. tuberculosis resistance, on top of associated conditions such as alcohol and drug abuse and problems in patient adherence.
The 2011 WHO MDR-TB guidelines 32 have divided anti-TB drugs into groups, based on their efficiency and safety (Table 2) . The strategies for the treatment of drug-resistant TB (DR-TB) have recently been updated 32, 33 .
The treatment of mono-and poly-drug-resistant TB is largely based on the recommendations from the 2011 WHO Guidelines for the programmatic management of DR-TB mentioned above, which underwent systematic review and analysis of the best treatment evidence base 28 . Table 3 summarizes the stepwise approach recommended for the design of treatment regimens. There are presently two approaches TB programs are using, including both standardized and individualized regimens.
Suspected MDR-TB cases should be confirmed by DST whenever possible. In the absence of patient-specific DST, data from representative patient populations are used to develop and design standardized empiric treatment regimens, which are likely to include a sufficient number of active drugs to ensure treatment success.
However, the individualized approach has to be preferred. Each treatment regimen is designed based on both the patient's past history of TB treatment and the individual DST results. The recommended empiric regimen BRN Rev. 2015;1
for MDR-TB treatment should include a minimum of four potentially active drugs: a later generation fluoroquinolone (moxifloxacin, gatifloxacin, or levofloxacin) and an injectable aminoglycoside (amikacin, capreomycin, or kanamycin), plus any first-line drug to which the isolate is susceptible such as pyrazinamide, plus the addition of one drug from group 4 (cycloserine, para-aminosalicylic acid, terizidone, prothionamide, or ethionamide) ( Table 3 ). The drugs categorized as WHO class 5 should be included only if four potential active drugs are not available. The core principle is that at least four drugs to which M. tuberculosis is likely to be susceptible are needed.
The minimum duration of the intensive phase (using injectables) is eight months, while the continuation phase will last for 12-18 months. The total treatment duration recommended by the WHO based on the available evidence is at least 20 months. The duration of treatment should be guided by culture conversion: 18 months need to be added to the date of the first negative culture. Where patients show no clinical response and their M. tuberculosis cultures are consistently positive, the underlying causes should be identified. The most common causes are incorrect drug dosage, quality of drug supply, non-adherence factors, malabsorption, and comorbidities.
NEW TRIALS AND NEW DRUGS
Fluoroquinolones are being studied for their interesting bactericidal activity and potential capacity to reduce the treatment duration. Bedaquiline selectively targets the proton pump of adenosine triphosphate (ATP) synthesis, leading to inadequate ATP production and lack of intracellular energy supporting replication 38 . The bactericidal activity of bedaquiline is superior to that of H and R 38 . The results of phase II trials suggest that a standard two-month treatment regimen with bedaquiline added to an optimized background regimen (OBR) designed as per WHO recommendations increase culture and sputum smear conversion rates while lowering acquired resistance to companion drugs in newly diagnosed MDR-TB cases 39, 40 . Both the WHO 41 and the US Centers for Disease Control and Prevention (CDC) 42 have published consistent recommendations supporting the use of bedaquiline under the following conditions: the dose of 400 mg daily for two weeks (then 200 mg three-times a week for 22 weeks) should be used; bedaquiline should be added to an OBR regimen to treat adult MDR-TB cases; pharmacovigilance needs to be in place; informed consent is compulsory and QT monitoring facilities have to be available 41, 42 . The simultaneous use of bedaquiline and delamanid is not recommended because of the increased risk of QT prolongation and death 41, 42 . Phase III trials of the use of bedaquiline to shorten the treatment duration are presently ongoing.
Both delamanid (previously known as OPC-67683) and pretomanid inhibit the synthesis of mycolic acids of the mycobacterial wall, being active against replicating and anaerobic, non-replicating M. tuberculosis persisters. They have shown potentialities to improve treatment outcomes for MDR-TB 5,43-51 . They are currently in phase II/III clinical trials (Table 4) 45, 46, 48, 50, 51 . Based on the available evidence, the WHO 47 recommends the use of delamanid at a dose of 100 mg twice daily for six months, added to OBR in adults, when pharmacovigilance is in place and informed consent ensured. Although anecdotal evidence suggests that delamanid is effective and safe in children 5 , two clinical trials (NCT01859923 and NCT01856634) are presently investigating delamanid in the treatment of pediatric MDR-TB.
Diacon, et al. assessed the 14-day early bactericidal activity of a regimen composed of pretomanid, moxifloxacin, and Z, which proved to be significantly higher than that of bedaquiline alone, bedaquiline plus Z, bedaquiline plus pretomanid (but not to pretomanid plus Z) and comparable to that of the standard treatment regimen (HRZ with S or E). Interestingly, the addition of Z increased the activity of both bedaquiline and pretomanid 39, [48] [49] [50] .
In a recent phase IIb trial, the bactericidal activity of a new eight-week regimen including moxifloxacin, pretomanid, Z, and clofazimine was compared to that of the standard (WHO-recommended) anti-TB regimen for drug susceptible and DR-TB. The new regimen yielded higher bactericidal activity than the current WHO-recommended regimen after two months of treatment 51 .
RE-PROPOSED DRUGS
Among re-proposed anti-TB drugs, linezolid and meropenem clavulanate recently raised special interest.
Linezolid, a first-generation oxazolidinone, proved to be effective against M. tuberculosis when added to OBR, although adverse events were common [52] [53] [54] [55] [56] . A recent meta-analysis 56 based on individual data provided updated evidence on efficacy, safety, and tolerability of linezolid, as well as indirect evidence that a proper treatment drug monitoring approach to drug dosage can reduce linezolid toxicity 57 .
An interesting study from The Netherlands 58 shows that clarithromycin is able to boost the blood levels of linezolid, so that a lower dose of drug can be administered; less adverse events are then expected together with economic savings. The available evidence suggest Treatments were well tolerated and appeared safe. One patient on Pto + moxifloxacin + Z was withdrawn because of corrected QT interval changes exceeding pre-specified criteria.
Diacon, et al. 48 (Continue) that a linezolid dose between 300 and 600 mg per day is adequate to treat MDR-/XDR-TB when added to OBR [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] .
Meropenem clavulanate is also active against M. tuberculosis and appears to be well tolerated.
In a case-control study 62 it demonstrated, when added to linezolid-containing OBR, to improve sputum smear and culture conversion in MDRand XDR-TB cases. Further studies are necessary to define the role of this drug within the anti-MDR-TB armamentarium.
Other drugs, including sulfamides and mefloquine, have been used in difficult-to-treat cases, although the evidence is anecdotal [63] [64] [65] . OBR: optimized background regimen; C: culture; HR: hazard ratio; CI: confidence interval; CFU: colony-forming unit; SS: sputum smear; AE: adverse events; BCI: Bayesian credibility interval; BID: twice daily; QT: measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle; ECG: electrocardiogram; EBA: early bactericidal activity; DS: drug-susceptible; DR: drug-resistant; MDR-TB: multidrug-resistant tuberculosis; PTB: pulmonary tuberculosis; DR-TB: drug-resistant-tuberculosis; TB: tuberculosis; WBA: whole blood bactericidal activity; OB: once daily; MIC: minimum inhibitory concentration; H: isoniazid; R: rifampicin; Z: pyrazinamide; E: ethambutol; Bql: bedaquiline; Pto: pretomanid; Del: delamanid; Cfz: cloafazimine. 
NEW EFFECTIVE ANTI-TUBERCULOSIS REGIMENS: A STEP FORWARD
The new, innovative global public health intervention recently approved by the WHO and known as "End TB Strategy" 1 , supports the vision of a TB-free world with zero death, zero disease, and zero suffering due to TB [66] [67] [68] .
While rapid diagnosis and effective treatment of (infectious) cases are the pillars of TB control, a more aggressive approach based on diagnosis and treatment of latently infected individuals has been proposed in the context of TB elimination to ensure future, TB-free, generations.
Within the Pillar 1 adequate, universally accessed treatment is a prerequisite to reach TB elimination.
New shorter, cheap, safe, and effective anti-TB regimens are necessary to boost TB elimination 69, 70 .
The new drugs have shown promising steps toward a new universal regimen 51 that, bypassing the H and R bottleneck, allows to treat all HIV-coinfected patients (with no interference with antiretrovirals) independently from their drug-susceptible or DR status 71 .
There are obvious potentialities to shorten the treatment duration and, consequently, to improve patient adherence and reduce the selection of resistant mutants of M. tuberculosis.
The rational use of the existing drugs and regimens is necessary if we want to ensure them a long life 72 .
